全球智能抗菌医疗涂料和表面市场 – 行业趋势和 2030 年预测

智能抗菌医疗涂料和表面市场分析和规模

抗菌涂层是一种表面覆盖物，含有有效抑制细菌和真菌生长的活性成分。抗菌涂层可能包括溶剂型、水性、液体或粉末涂层。发展中经济体和不断增加的研发投资正在推动市场发展，并为创新和市场扩张创造机会。                      

Data Bridge Market Research 分析，全球智能抗菌医疗涂料和表面市场在 2022 年为 101.5 亿美元，预计到 2030 年将达到 289.5375 亿美元，预计在预测期内的复合年增长率为 14.00%。由于对智能抗菌医疗涂料和表面抗菌涂层的需求不断增长，“医疗设施”在智能抗菌医疗涂料和表面市场的应用领域中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

智能抗菌医疗涂料和表面市场范围和细分

Market Definition

Smart antimicrobial coatings and surfaces are used to reduce the spread of germs and infections.  In the healthcare sector, the coatings minimize the risk of infection during medical procedures. Smart antimicrobial healthcare coatings and surfaces are used on various medical tools and products such as catheters, surgical devices, medical electronics, medical instruments, trays, among others and are also used in equipment such as textiles, masks, gloves, and carpeting.

Global Smart Antimicrobial Healthcare Coatings and Surfaces Market Dynamics

Drivers

• Increasing prevalence of chronic diseases

The globally increasing burden of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune diseases is a major driver of the protein therapy market. Protein-based therapies offer targeted therapeutic options with high specificity and efficacy, making them valuable in the management and treatment of these complex diseases.

• Technological advancements in microbiology

Advances in microbiology, including recombinant DNA technology, monoclonal antibody production, and protein expression systems, have revolutionized the development of Smart Antimicrobial Healthcare Coatings and Surfaces. These technological advancements have enabled the production of highly specific and potent protein drugs with improved pharmacokinetics and reduced immunogenicity.

• Increasing demand for personalized medicine

The demand for personalized medicine is increasing, which requires tailoring treatment based on a person's genetic profile, disease characteristics, and response to treatment. Protein drugs, such as monoclonal and bispecific antibodies, can be tailored to target specific molecular targets, enabling individualized and precise therapies.

Opportunities

• Rising demand for targeted therapies

There is a demand for targeted therapies that offer high specificity and efficacy in treating various diseases. Protein therapies, such as monoclonal antibodies and fusion proteins, offer targeted approaches by binding specifically to disease-related targets, leading to improved treatment outcomes. This gives the market an opportunity to develop and commercialize new protein-based drugs that target specific diseases.

• Expansion in emerging markets

Emerging markets such as China, India, Brazil and other countries in Asia and Latin America are seeing significant increases in healthcare spending and access to advanced treatments. The expansion creates a favorable market environment for protein therapy, as these areas offer untapped potential and large patient populations. Protein drugs can be adapted and tailored to the specific needs of these markets, thus increasing market reach and revenue.

Restraints

• High development and manufacturing costs

Development and manufacturing of protein drugs involves complex processes, extensive research, and strict quality control measures. This results in high expenditure on research and development, manufacturing and regulatory compliance. High costs significantly limit the market and the availability and affordability of protein-based therapies, especially in resource-constrained healthcare systems.

• Stringent regulatory requirements

Protein therapeutic preparations are subject to strict requirements for safety, efficacy, and quality. Regulatory agencies set strict guidelines and standards for their development, testing, and approval. Compliance with these regulatory requirements can be time-consuming, expensive, and resource-intensive, resulting in delays in product development and time-to-market. A strict regulatory environment restricts the market, especially for small and medium-sized biopharmaceutical companies with limited resources.

Challenges

• Manufacturing complexity and scalability

Antimicrobial coatings often require complex manufacturing processes, including cell culture, expression, purification, and formulation. Achieving consistent quality, scalability and cost-effectiveness in mass production can be challenging. Manufacturing challenges can limit the availability and affordability of these surfaces, particularly in treating rare or rare diseases. Overcoming manufacturing complexities and building strong manufacturing capabilities are critical for market growth and accessibility.

• Intellectual property and patent expiration

Intellectual property rights and patent protection are vital in the protein medicine market. The industry faces patent expiration challenges as many pioneering protein therapies are nearing the end of their patent exclusivity. This allows biosimilars and generic versions to enter the market, increasing competition and potential price erosion. Companies must focus on developing innovative protein-based therapies and generate new patents to maintain a competitive advantage.

Recent Development

• In June 2022, DuPont has announced completion of the previously-announced sale of its Biomaterials business unit to the Huafon Group for a purchase price of approximately USD 240 million

Global Smart Antimicrobial Healthcare Coatings and Surfaces Market Scope

全球智能抗菌医疗涂料和表面市场根据类型和应用进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

• 银和纳米银
• 水凝胶
• 壳聚糖
• 硅烷
• 硫酸盐
• 石墨烯
• 碳纳米管

应用

• 医疗设施
• 医疗植入物
• 手术设备
• 兽医
• 实验室设备

全球智能抗菌医疗涂料和表面市场区域分析/见解

对全球智能抗菌医疗涂料和表面市场进行了分析，并按国家、产品、应用、功能和最终用户提供了市场规模洞察和趋势。

全球智能抗菌医疗涂料和表面市场报告涵盖的国家包括美国、加拿大、墨西哥、德国、意大利、英国、法国、西班牙、荷兰、比利时、瑞士、土耳其、俄罗斯、欧洲其他地区、日本、中国、印度、韩国、澳大利亚、新加坡、马来西亚、泰国、印度尼西亚、菲律宾、亚太其他地区、巴西、阿根廷、南美洲其他地区、南非、沙特阿拉伯、阿联酋、埃及、以色列、中东和非洲其他地区。

由于先进技术的采用、优惠报销政策的普及和人民生活水平的提高，北美预计将在全球智能抗菌医疗涂料和表面市场中占据主导地位。

由于对先进治疗方案的需求不断增加以及人均收入不断提高，预计亚太地区将在 2023 年至 2030 年的预测期内以最高的增长率增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

全球智能抗菌医疗涂料和表面市场还为您提供了每个国家/地区资本设备医疗支出增长、智能抗菌医疗涂料和表面市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对智能抗菌医疗涂料和表面市场的影响的详细市场分析。数据适用于 2015-2020 年的历史时期。

竞争格局和智能抗菌医疗涂料和表面市场份额分析

全球智能抗菌医疗涂料和表面市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对全球智能抗菌医疗涂料和表面市场的关注有关。

全球智能抗菌医疗涂料和表面市场的一些主要参与者包括：

• AkzoNobel NV（荷兰）
• AK Steel Corp.（印度）
• 龙沙（瑞士）
• Diamond Vogel（美国）
• 杜邦（美国）
• 艾仕得涂料系统（美国）
• 日本涂料控股有限公司 (印度)
• PPG工业公司（美国）
• RPM International Inc.（美国）
• Koninklijke DSM NV（荷兰）
• Burke 工业涂料 (美国)
• 宣威·威廉姆斯公司（美国）
• 特洛伊公司 (美国)

SKU-65422